Schizophrenia  >>  JNJ-37822681  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JNJ-37822681 / J&J
NCT01812642 / 2007-007669-20: A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia

Completed
2
33
Europe, RoW
JNJ-37822681, Placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
12/08
12/08
NCT00728195 / 2007-007083-22: An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

Checkmark P2 data
Sep 2012 - Sep 2012: P2 data
Checkmark P2 data
Apr 2012 - Apr 2012: P2 data
Completed
2
498
Europe, RoW
JNJ-37822681, Olanzapine, Placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
02/10
02/10

Download Options